ReviewNature reviews. Rheumatology2017
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.
Review in Nature reviews. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 5 syntheses or guidelines pooled it, 225 citations in OpenAlex.
- The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.Rheumatology (Oxford, England) · 2026Guideline
- Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.Rheumatology (Oxford, England) · 2024Pooled it
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- Gene and miRNA expression in giant cell arteritis-a concise systematic review of significantly modified studies.Clinical rheumatology · 2019Pooled it
- Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.PLoS medicine · 2023Trial
- Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2022Trial
- Trial
- Musculoskeletal ultrasound findings in GCA with PMR and isolated PMR.Rheumatology advances in practice · 2026Article
- Modern Management of Isolated Polymyalgia Rheumatica.Rheumatology and therapy · 2025Review
- Article
- The distinct phenotype of subclinical giant cell arteritis in polymyalgia rheumatica: evidence from a PMR fast-track clinic.EULAR rheumatology open · 2025Article
- Biomarkers of ocular manifestation in newly diagnosed giant cell arteritis.BMC ophthalmology · 2025Article
- Article
- Review
- Clinical features, imaging use, and management in giant cell arteritis: a retrospective single-center study.Clinical rheumatology · 2024Article
- Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.Journal of clinical medicine · 2024Review
- Polymyalgia Rheumatica Complicated by Nephrotic Syndrome in a Nonagenarian: A Case Report.Cureus · 2024Article
- Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study.Doklady. Biochemistry and biophysics · 2024Article
- Supra-aortal intima-media thickness in treatment-naïve polymyalgia patients compared to matched controls.Clinical rheumatology · 2024Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.